Feasibility of a mobile application guiding patients with inflammatory bowel disease during biologic treatment

Completed

• Conditions: Crohn's disease and ulcerative colitis; Inflammatory bowel disease; 10017969

• Registration Number: NL-OMON48345
• Lead Sponsor: Rijnstate Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 55

Inclusion Criteria

- Diagnosis of inflammatory bowel disease (including Crohn*s disease,
ulcerative colitis and IBD-unclassified) based on a combination of clinical,
endoscopic, histologic and radiologic internationally accepted criteria.
- Treatment with biologics, for the purpose of this study only patients with
biologics that are administered intravenously in the hospital every 4-10 weeks
are included (infliximab or vedoluzimab).
- Aged 18 years or older.
- Having (access to) a tablet or smartphone.
- Having (access to) working internet connection.
- Ability to read and understand the Dutch language.

Exclusion Criteria

- Patients recently started with biologic treatment (< 3 maanden)
- No access to a tablet or smartphone
- No internet access

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primarily, we will evaluate the satisfaction of patients with the mobile<br /><br>application, actual use and adherence. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The satisfaction of care providers and change in number of outpatient visits<br /><br>and telephone contacts will also be evaluated. </p><br>